Originally from St. Petersburg, Russia, Dr. Blagosklonny earned his M.D. in internal medicine and Ph.D. in experimental medicine and cardiology from the prestigious First Pavlov State Medical University.

Shortly after, he came to the United States and became an assistant professor at New York Medical College before switching to a career in the industry On ResearchGate.net. Blagosklonny worked as a senior scientist at the Ordway Research Institute in Albany, New York before holding his current title and position as the Professor of Oncology at the Roswell Park Cancer Institute based in Buffalo, New York.

Highly accomplished and revered, Mikhail Blagosklonny has published over 300 articles, reviews and books in Cancer Research, Aging, PLOS ONE, International Journal of Cancer, The American Journal of Pathology, Autophagy, and Cancer Biology & Therapy. Not only has he put in a lot of effort to get his research published, but he has also held the positions of Founding Editor, Co-Founder, Co-Editor, and Editor-in-Chief.

While Mikhail Blagosklonny has published on a broad range of topics revolving around cancer, his interest lately seems to focus on the link between cancer and aging and finding links and similarities in their pathways. Having dedicated many years to studying the molecular and cellular biology of oncogenes, genes capable of transforming a cell into a tumor cell, and tumor suppressors, Blagosklonny has helped reveal that rapamycin, a cancer drug, can help extend the longevity of life.

Specifically, he has hypothesized a link between MTOR signaling in aging and cancer at http://www.nature.com/cdd/about/biographies.html. MTOR signaling, or the mechanistic target of rapamycin, regulate many cell functions and processes including cell growth, proliferation motility, and survival, to name a few. First discovered in the soils of Easter Island in the 1970s, the antifungal stops activity in the G1 phase of the cell cycle by suppressing the immune system. This is a significant finding because when the MTOR signaling pathway becomes deregulated, all kinds of problems can occur including diabetes, obesity, and cancers.

Recently, Blagosklonny and other scientists have also studied the mechanisms of aging, or biogerontology, and have found that decreased TOR activity has been found to increase lifespan. Blagosklonny has advocated for the use of rapamycin as an anti-aging drug and is considered one of the most passionate to speak of its wonders.


  1. Noor Jairo says:

    Rapamycin can inhibit this pathway and the deleterious effects that occur if the pathway were to continue in the deregulated state. It is the state of of what ukbestessays has put them that is very important and it is most likely be exactly what they know about too which very nice.